How Prior Authorization Works for Blue Cross GLP-1 Coverage

Authorization is granted per product and per indication rather than per molecule. A licensee or its pharmacy benefit manager publishes criteria for each covered product, the prescriber submits against that document, and any approval attaches to that specific product for a fixed term. Approval for tirzepatide as a diabetes drug does not carry over to the weight-management brand.

Find out which document governs before writing anything

Three parties can own the criteria. The licensee company publishes medical and pharmacy policies. The pharmacy benefit manager administering the drug list publishes its own criteria, sometimes under a different name than the insurer. And a self-funded employer can direct changes to either. Submitting against the wrong document is the most common reason a request comes back for more information.

Because every Blue Cross licensee is a separate company setting its own drug list, a criteria document found through a general web search may belong to a licensee in another state. The document number and effective date printed on the policy are the way to confirm it is the right one.

Two products, two criteria sets, one molecule

Semaglutide is approved as Ozempic for glycemic control in type 2 diabetes along with cardiovascular and kidney outcome uses, and as Wegovy for long-term weight reduction, cardiovascular risk reduction with established disease, and noncirrhotic metabolic dysfunction-associated steatohepatitis. Tirzepatide is approved as Mounjaro for type 2 diabetes and as Zepbound for weight reduction and for moderate to severe obstructive sleep apnea in adults with obesity.

Each of those approvals can carry its own review pathway, and the sleep apnea indication is the one people miss. It was added after the weight indication and is supported by a randomized trial in adults with obesity and moderate to severe disease, so a documented sleep study can put a request on a different track than a weight-only request.

What the request is assembled from

Element	Where it comes from	Why requests stall on it
Product and strength	The prescription itself	Written for the sibling brand the plan does not list
Indication being treated	The clinical record	Recorded code sits outside the product label
Objective measurements	Dated clinic visits	Self-reported or undated figures submitted
Treatment history	Chart notes and fill history	Duration and outcome of prior therapy missing
Supporting testing	Labs, sleep study, imaging	Ordered but not yet resulted when submitted
Criteria document	Licensee or benefit manager	Wrong version, wrong state, or superseded

The specific thresholds inside each criteria document vary by licensee, by product and by plan year, so the only reliable version is the one the plan publishes for that member. Working from a threshold quoted secondhand is how prescribers end up submitting twice.

Members waiting on a decision often want to understand those criteria themselves, and providers vary in how much they publish. LillyDirect and Henry Meds stay focused on their own products, while HealthRX keeps a reference page on GLP-1 insurance coverage that lays out how drug-list placement and indication drive an approval. None of it substitutes for the plan’s own document, but it makes the eventual request easier to read and to check.

Who submits, and what the clock looks like

The prescriber submits, usually through an electronic portal, occasionally by fax form. Members cannot file it themselves, though they can push it along and should confirm it was actually transmitted rather than queued. Federal rules set outer limits for plans subject to them: decisions on requests made before a service is received arrive within a defined window, and urgent requests move to a much shorter one.

Two practical habits shorten the wait. Ask for the reference number at submission, because without it nobody on a phone line can locate the request. And ask whether anything was returned as incomplete, since a request sitting in a pending queue and a request rejected for missing data look identical from the outside.

Approval is time-limited and product-specific

Authorizations are issued for a term, commonly six or twelve months, after which continuation has to be requested again. The approval also names a product. Switching between the two brands of the same molecule, or between manufacturers, generally requires a fresh request even when nothing clinical has changed. Members who assume approval covers the molecule discover otherwise at the counter.

Renewals fail for different reasons than first requests

Initial requests fail on missing documentation. Renewals fail on response criteria, meaning the plan asks whether the treatment worked and whether it is still being taken as prescribed. Gaps in the fill history read as non-adherence even when the gap was a supply problem, so a note explaining an interruption belongs in the renewal rather than nowhere.

While the request sits in a queue

Decisions take days at best and weeks in ordinary cases, and treatment interruption is not neutral with this class, since stopping produces predictable weight regain in the published maintenance data. That makes a parallel cash plan a reasonable hedge rather than a surrender.

Published cash prices span a wide band. Manufacturer channels post figures for the branded products, and supervised telehealth practices including Ro, Hims and Hers and FormBlends post monthly figures for compounded semaglutide or tirzepatide. A quoted price settles very little on its own, because what is being bought depends on the provider behind it: who prescribes, which pharmacy fills, and whether the consultation and shipping sit inside the number. Compounded preparations are not FDA-approved and are not reviewed by the agency for safety, effectiveness or manufacturing quality.

Frequently asked questions

Can a member start the authorization themselves?

No. The request has to come from the prescribing office because it draws on the clinical record. A member can supply missing pieces, confirm the plan and member identifiers are correct, and call to verify the submission arrived, which is often the difference between a two week wait and a five week one.

Does approval guarantee a low copay?

No. Authorization answers whether the plan will pay at all. What the member pays is set by the drug list placement and the plan design, so an approved product can still carry a significant share of cost. Those two questions are decided by different parts of the benefit and should be asked separately.

What happens if the plan changes benefit managers mid-year?

Existing approvals sometimes transfer and sometimes do not. Continuity provisions vary by contract, so the safe move is to confirm in writing that the authorization is recorded under the new administrator before the next refill, rather than discovering the gap at the pharmacy counter.

Is a sleep apnea diagnosis a different pathway?

It can be, because tirzepatide carries an approved indication for moderate to severe obstructive sleep apnea in adults with obesity. That route requires a documented diagnosis established through standard sleep testing, and the plan applies whatever review it has written for that indication, which may differ from the weight pathway